News
Zuellig Pharma expands Cialis footprint across Asia
The expanded ownership is expected to improve access to Cialis for millions of men in Asia affected by ED and BPH
- By IPP Bureau
| March 16, 2026
Zuellig Pharma, a leading healthcare solutions company in Asia, has officially acquired all rights to Cialis (Tadalafil) from Eli Lilly and Company in Hong Kong, Macau, and South Korea.
With this move, Zuellig Pharma now controls the trademarks, marketing authorizations, and license manufacturing know-how for Cialis, a treatment for erectile dysfunction (ED) and benign prostatic hyperplasia (BPH), across 11 Asian markets—expanding from the original eight. The company will continue promoting and distributing the brand in these regions.
The expanded ownership is expected to improve access to Cialis for millions of men in Asia affected by ED and BPH, reinforcing Zuellig Pharma’s strategy of building a strong portfolio of owned prescription healthcare products.
“Our acquisition of Cialis in three additional markets builds on the strong foundation we established two years ago and highlights our proven success in scaling trusted brands effectively through our commercial capabilities and deep expertise.
"As we broaden our footprint, we remain focused on delivering sustainable growth and advancing our purpose of making in-demand healthcare solutions more accessible to communities in Asia,” said John Graham, CEO of Zuellig Pharma.
